Navigation Links
Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
Date:7/14/2009

In addition to EZN/SPC2968 and EZN/SPC3042 Enzon has now received all the remaining six novel cancer drug candidates from Santaris Pharma and Enzon has announced the targets for four of these compounds: Her3, beta catenin, PIK3CA and the androgen receptor.

Pipeline Summary

In H1 2009 Santaris Pharma continued the progress for both the drug discovery programs and the drug development pipeline. At the end of June Santaris Pharma had four drugs in clinical development:

    - SPC3649, an LNA-antimiR(R) against microRNA-122, being
      developed for the treatment of HCV infections

    - EZN/SPC2968, a HIF-1alpha inhibitor, being developed for the
      treatment of various solid tumors

    - SPC2996, a Bcl-2 inhibitor, being developed for the
      treatment of cancer. Santaris Pharma has initiated the process of
      divesting this candidate

    - EZN3042, an LNA-based Survivin inhibitor, being developed
      for the treatment of various solid tumors

In addition to the four clinical development stage compounds Santaris Pharma and its partners have several other compounds in the discovery, research and preclinical stages, including the new apoB inhibitor, SPC4955 which now enters preclinical development and the PCSK9 lead candidates which are ready for pharmacological studies.

See Santaris Pharma's pipeline through this link: http://www.santaris.com/Library/documents/Santaris_Pharma_Interim_Report_1_Ja nuary_to_30_June_2009.pdf

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

Research

During H1 2009 Santaris Pharma and/or partners have published six scientific articles and more have been submitted
'/>"/>

SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Fast, semi-automatic ... chemistry in documents ChemAxon , ... consulting services for life science research, launches ChemCurator, ... Markush structures from documents. Markush structures ... however generating and understanding Markush structures is a ...
(Date:9/30/2014)... Md., Sept. 30, 2014 BioHealth Innovation, ... commercializing market-relevant biohealth innovations and increasing access to early-stage ... today that venture capitalist, Tania Fernandez , Ph.D., ... Dr. Fernandez will be a member of the management ... provide up to $50 million in seed and early-stage ...
(Date:9/30/2014)... The custom stainless steel fabrication company HOLLOWAY AMERICA ... Boston Area Chapter of ISPE (International Society for Pharmaceutical ... Wed., Oct. 1 at Gillette Stadium Clubhouse in Foxborough, ... ISPE Boston’s long history, with more than 375 exhibitors ... , HOLLOWAY AMERICA President David Simpson is looking forward ...
(Date:9/30/2014)... September 30, 2014 On September 11, Pharma ... Sherley in anticipation of a session that he will lead ... Summit,” scheduled for February 17-18, 2015 in London. In ... IQ asked Dr. Sherley to respond to several questions on ... challenges to evaluating stem cell toxicity, and future trends in ...
Breaking Biology Technology:ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4
... Arginine vasopressin (AVP) receptor antagonist now approved in single-use ... ... 22 Astellas Pharma US, Inc. today,announced that the U.S. ... of Vaprisol: Vaprisol(R) (conivaptan hydrochloride,injection) Premixed in 5% Dextrose. Discovered ...
... November 18, 2008, WITTEN, Germany, October 22 ... fiscal year,ended June 30, 2008, on October 21. According ... SEC the company yielded sales of its cosmetics and ... a decrease,of 44% as compared with sales revenues of ...
... Halozyme Therapeutics,Inc. (Nasdaq: HALO ), a biopharmaceutical ... that it will present at three upcoming investor conferences:, ... the Hyatt Regency in La,Jolla, Calif. on Monday, October ... -- Oppenheimer,s 19th Annual Healthcare Conference to be ...
Cached Biology Technology:FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 2FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 3FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 4Sangui Biotech International, Inc., Reports Sales Decrease, Continued Losses 2Halozyme Therapeutics to Present at Upcoming Investor Conferences 2
(Date:9/30/2014)... Mass. , Sept. 30, 2014 /PRNewswire/ ... control solutions for the biotech and power ... its new RECONN Bioprocess Manager, an easy-to-use ... solution geared towards bioprocess development laboratories. ... have disparate bioreactor and analyzer systems. Accessing ...
(Date:9/30/2014)... ARLINGTON HEIGHTS, Ill. (September 30, 2014) People who ... they can do to control their asthma besides properly ... to a new article in the Annals of ... the American College of Allergy, Asthma and Immunology (ACAAI), ... by examining their lifestyle. The woman described in the ...
(Date:9/29/2014)... called Clostridium ramosum , coupled with a high-fat diet, ... this week in mBio , the online open-access journal ... team from the German Institute of Human Nutrition Potsdam-Rehbruecke in ... C. ramosum gained weight when fed a high-fat diet. ... less obese even when consuming a high-fat diet, and mice ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Asthma symptoms kicking up? Check your exposure to air pollution 2Gut bacteria promote obesity in mice 2
... The U.S. Food and Drug Administration (FDA) granted market ... bionic eye to be approved for patients in the ... with support from the National Science Foundation (NSF). ... transmits images from a small, eye-glass-mounted camera wirelessly to ...
... be an early step toward new treatments for people with ... probiotic supplement can help male mice produce healthier bones. ... researchers report in the Journal of Cellular Physiology . ... bone loss, though it,s unclear exactly why," said lead author ...
... that cold-blooded animals, such as worms, flies and fish ... known exactly why. , Researchers at the University of ... that promotes longevity of roundworms in cold environmentsand this ... , "This raises the intriguing possibility that exposure to ...
Cached Biology News:Artificial retina receives FDA approval 2Artificial retina receives FDA approval 3Artificial retina receives FDA approval 4Artificial retina receives FDA approval 5Building healthy bones takes guts 2Stay cool and live longer? 2